Simplify Logo

Full-Time

Bioprocess Development Associate

Posted on 6/26/2024

Orca Bio

Orca Bio

51-200 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Compensation Overview

$70k - $90kAnnually

+ Pre-IPO Equity

Junior, Mid

Menlo Park, CA, USA

This position is onsite in Menlo Park, CA.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree in Chemical Engineering, Biotechnology, Biochemistry or related field
  • 2-5 years of experience in process sciences or manufacturing
  • Competence in aseptic technique, mammalian seed train maintenance, media, buffer preparation, and using lab equipment including laminar flow hoods, incubators, autoclaves
  • Hands on experience with analytical techniques for antibody characterization, processing and analyzing samples
  • Experience executing cell culture experiments, antibody expression and purification
  • Willingness to learn flow cytometry for analysis of cell populations
  • Willingness to work in a BSL-2 environment
Responsibilities
  • Design, optimize and implement process improvements related to protein production and bioconjugation of protein-protein complexes
  • Design and execute studies to develop and optimize cell culture and purification steps; perform analytical testing; preform troubleshooting and investigations; perform stability and formulation studies
  • Collaborate with external vendors and internal teams to design and implement novel technologies for optimizing protein-conjugate development
  • Support continuous improvements of records and follow operating procedures with strong attention to detail
  • Maintain detailed records of experiments, have good data management and documentation skills
  • Instrument set-up and preparation, maintenance, troubleshooting, and operation

Orca Bio operates in the biotechnology field, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company aims to enhance these therapies to make them safer and more effective, ultimately improving patient outcomes. Orca Bio's products are designed for healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to significantly impact healthcare by advancing cell therapy treatments for conditions that currently have limited options.

Company Stage

Series D

Total Funding

$375M

Headquarters

Menlo Park, California

Founded

2016

Growth & Insights
Headcount

6 month growth

14%

1 year growth

18%

2 year growth

38%
Simplify Jobs

Simplify's Take

What believers are saying

  • Orca Bio's promising clinical data, including high relapse-free survival rates, highlight the potential for curative treatments in challenging patient groups.
  • The company's participation in prestigious conferences like the J.P. Morgan Healthcare Conference and the American Society of Hematology Annual Meeting underscores its industry recognition and thought leadership.
  • Orca Bio's strong team culture and commitment to employee value make it an attractive workplace for talented individuals in the biotechnology field.

What critics are saying

  • The competitive landscape in cell therapy and biotechnology requires continuous innovation to maintain a leading position.
  • Clinical trials and regulatory approvals are inherently risky and can lead to delays or failures, impacting the company's progress and financial stability.

What makes Orca Bio unique

  • Orca Bio's focus on high-precision cell therapies for cancer, autoimmune diseases, and genetic blood disorders sets it apart in the biotechnology sector.
  • Their proprietary single-cell precision manufacturing platform offers uniquely-defined products that aim to transform allogeneic cell therapy.
  • Orca Bio's investigational therapies, such as Orca-T and Orca-Q, demonstrate significantly better outcomes with fewer risks compared to standard treatments.
INACTIVE